Upgrade Autoimmune Diagnostic Testing Using Multiplex Technology

Gold Standard Diagnostics’ assays generate more results and revenue with less overhead.

Upgrade Autoimmune Diagnostic Testing Using Multiplex Technology

For Gold Standard DiagnosticsCheryl Cink, 530-219-3949

Simplify clinical diagnosis of autoimmune disease with comprehensive offering of . GSD has partnered with Theradiag (formerly known as Biomedical Diagnostics, BMD) to provide laboratories with the for detection of the autoantibodies associated with connective tissue diseases, CREST syndrome, systemic lupus erythematosus (SLE), rheumatoid arthritis, vasculitis, polymyositis, dermatomyositis, scleroderma, Sjögren syndrome, thyroid syndromes, Celiac and many others. Major benefits of the suite include: up to 13 results in a single well, reduced labor and overhead, increased throughput, small sample volume and full automation.

Autoimmune diagnosis can be complicated and expensive. allows clinicians to perform an entire panel of assays in a single well and generate the same results with drastically less laboratory resources and patient sample requirements. For example, the panel simultaneously detects antibodies for dsDNA, SS-A, SS-B, RNP, Sm, Jo-1, Scl-70, ribosomal P and centromere -- all in a single well. Capture major cost savings through decreased labor and higher throughput while remaining eligible for the same reimbursements as performing a panel of assays individually.

The employs Luminex® xMAP® technology, along with proprietary MLX booster™ software to provide rapid and precise results for autoimmune diagnosis. xMAP® uses proprietary microsphere beads for multiplexing. A single well can contain up to 500 microsphere beads, each coated with a reagent specific to a particular assay. The beads are color coded, allowing for accurate, automated reading of results by an advanced optical system.

also offers a large number of for early autoimmune screening and to expand beyond the scope of tests available in the FIDIS™ format. All ELISA assays are fully validated as and deploy seamlessly on the . Realize maximum laboratory benefit quickly and easily through GSD’s outstanding setup, service and support for the entire solution of reagents and instrumentation.

Through a host of patent-pending features, the delivers exceptional power and flexibility in a small size. The dual function analyzer provides complete, walk-away automation of 192 patient samples in only a 2’ by 2’ space. Completely open architecture allows any EIA or CLIA protocol to be programmed, and up to eight different protocols to run in a single batch. Intuitive and robust software further enriches the , making it the total laboratory automation solution.

More information:

| (530) 759-8000 |

provides comprehensive diagnostic solutions that improve lab efficiency and minimize overall costs. Through an extensive product menu, automated instrument platforms, and outstanding customer service, GSD solves real laboratory problems. The result is a seamless laboratory experience achieved through an integrated approach.

More information is available at

has over 25 years of experience in the autoimmune disorder diagnostics market. It is currently moving into the theranostic testing market to improve biotherapy monitoring, including for autoimmune diseases. The company is based in Marne la Vallée (France) and has approximately 50 employees.

For more information about the company, visit:

Suggested Articles

Out of options, Tocagen will become Forte Biosciences’ route to the public markets through an all-stock reverse merger.

Reich co-founded Effector and served as its SVP of research but has moved on to take up the CSO position at Turning Point Therapeutics.

BioMarin’s hemophilia A drug has been set an Aug. 21 PDUFA date as the California biotech looks to gain a speedy approval.